Biological Products, (No Diagnostic Substances)
| Institution | Shares | Value | Ownership % | Change | Filing Date |
|---|---|---|---|---|---|
| BlackRock, Inc. | 38.36M | $321.0M | 17.02% | +1.52M | 2026-06-30 |
| STATE STREET CORP | 17.12M | $143.0M | 7.60% | +3.03M | 2026-06-30 |
| VANGUARD CAPITAL MANAGEMENT LLC | 10.10M | $84.0M | 4.48% | -203.1K | 2026-06-30 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 10.09M | $84.0M | 4.48% | +1.22M | 2026-06-30 |
| Rubric Capital Management LP | 9.34M | $78.0M | 4.14% | +7.53M | 2026-06-30 |
| Capital Research Global Investors | 8.76M | $73.0M | 3.89% | -2.43M | 2026-06-30 |
| FIRST TRUST ADVISORS LP | 7.80M | $65.0M | 3.46% | +7.44M | 2026-06-30 |
| GEODE CAPITAL MANAGEMENT, LLC | 6.06M | $50.0M | 2.69% | +235.9K | 2026-06-30 |
| Caligan Partners LP | 6.03M | $50.0M | 2.67% | +968.5K | 2026-06-30 |
| D. E. Shaw & Co., Inc. | 5.27M | $44.0M | 2.34% | +4.71M | 2026-06-30 |
